{"id":1589,"date":"2020-10-15T09:31:35","date_gmt":"2020-10-15T16:31:35","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=1589"},"modified":"2020-10-16T09:32:34","modified_gmt":"2020-10-16T16:32:34","slug":"safety-and-immunogenicity-of-two-rna-based-covid-19-vaccine-candidates","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/10\/15\/safety-and-immunogenicity-of-two-rna-based-covid-19-vaccine-candidates\/","title":{"rendered":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates"},"content":{"rendered":"<ul>\n<li>In an ongoing randomized controlled phase 1 trial of RNA-vaccine candidates BNT162b1 and BNT162b2 (n=195), both vaccine candidates elicited similar dose-dependent SARS-CoV-2 neutralizing titers, which were similar to titers of a panel of SARS-CoV-2 convalescent serum samples. BNT162b2 was associated with a lower incidence and severity of systemic reactions than BNT162b1, particularly in older adults, supporting its selection for advancement to phase 2-3 evaluations.<\/li>\n<\/ul>\n<p>Walsh et al. (Oct 14, 2020). Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine. <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2027906\">https:\/\/doi.org\/10.1056\/NEJMoa2027906<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In an ongoing randomized controlled phase 1 trial of RNA-vaccine candidates BNT162b1 and BNT162b2 (n=195), both vaccine candidates elicited similar dose-dependent SARS-CoV-2 neutralizing titers, which were similar to titers of a panel of SARS-CoV-2 convalescent serum samples. BNT162b2 was associated with a lower incidence and severity of systemic reactions than BNT162b1, particularly in older adults,&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/10\/15\/safety-and-immunogenicity-of-two-rna-based-covid-19-vaccine-candidates\/\">Read more<\/a><\/div>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-1589","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/1589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=1589"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/1589\/revisions"}],"predecessor-version":[{"id":1590,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/1589\/revisions\/1590"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=1589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=1589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=1589"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=1589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}